BR112015032554A2 - Moduladores do receptor de bradicinina e seu uso - Google Patents

Moduladores do receptor de bradicinina e seu uso

Info

Publication number
BR112015032554A2
BR112015032554A2 BR112015032554A BR112015032554A BR112015032554A2 BR 112015032554 A2 BR112015032554 A2 BR 112015032554A2 BR 112015032554 A BR112015032554 A BR 112015032554A BR 112015032554 A BR112015032554 A BR 112015032554A BR 112015032554 A2 BR112015032554 A2 BR 112015032554A2
Authority
BR
Brazil
Prior art keywords
receptor modulators
bradykinin receptor
bradykinin
hyperalgesia
cardiovascular
Prior art date
Application number
BR112015032554A
Other languages
English (en)
Other versions
BR112015032554A8 (pt
Inventor
Ribeiro Chagas Jair
Original Assignee
Sepia Pesquisa E Desenvolvimento
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepia Pesquisa E Desenvolvimento filed Critical Sepia Pesquisa E Desenvolvimento
Publication of BR112015032554A2 publication Critical patent/BR112015032554A2/pt
Publication of BR112015032554A8 publication Critical patent/BR112015032554A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/18—Kallidins; Bradykinins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

MODULADORES DO RECEPTOR DE BRADICININA E SEU USO. Esta invenção refere-se geralmente a novos peptídeos biológicos e purificadas, como os moduladores de receptores da bradicinina, para uso no tratamento e/ou prevenção de doenças inflamatórias, dor, hiperalgesia, doenças isquêmicas cardiovasculares e/ou cerebrais, em indivíduos que dele necessitam.
BR112015032554A 2013-06-25 2014-06-24 moduladores do receptor de bradicinina e seu uso BR112015032554A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH11682013 2013-06-25
PCT/IB2014/001162 WO2014207534A2 (en) 2013-06-25 2014-06-24 Bradykinin receptor modulators and use thereof

Publications (2)

Publication Number Publication Date
BR112015032554A2 true BR112015032554A2 (pt) 2017-08-22
BR112015032554A8 BR112015032554A8 (pt) 2018-01-23

Family

ID=52142768

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015032554A BR112015032554A8 (pt) 2013-06-25 2014-06-24 moduladores do receptor de bradicinina e seu uso

Country Status (5)

Country Link
US (1) US9920096B2 (pt)
EP (1) EP3013851A4 (pt)
JP (1) JP2016528192A (pt)
BR (1) BR112015032554A8 (pt)
WO (1) WO2014207534A2 (pt)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4693993A (en) 1985-06-13 1987-09-15 Stewart John M Bradykinin antagonist peptides
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
JPH07508510A (ja) * 1992-06-05 1995-09-21 エス・アール・アイ・インターナシヨナル 血小板由来増殖因子（ｐｄｇｆ）活性
JPH07330795A (ja) 1994-06-07 1995-12-19 Toagosei Co Ltd ペプチドおよびモノクローナル抗体
AU3935897A (en) 1996-08-19 1998-03-06 Universite De Sherbrooke B1-bradykinin receptor antagonists and use thereof
US20020165174A1 (en) * 1997-01-31 2002-11-07 Gill Parkash S. Methods and compositions for antisense VEGF oligonucleotides
JP2001002586A (ja) 1999-06-21 2001-01-09 Toagosei Co Ltd 重粒子線療法用薬剤
EP1248642A4 (en) * 2000-01-18 2005-05-18 Ludwig Inst Cancer Res PEPTIDOMIMETIC INHIBITOR OF VEGF AND VEGF-C AND -D
DE10141749A1 (de) 2000-08-29 2002-03-14 Max Delbrueck Centrum Mittel zur Beeinflussung der Angiogenese
DK1844337T3 (da) * 2005-01-24 2013-09-30 Pepscan Systems Bv Bindingsforbindelser, immunogene forbindelser og peptidmimetika
JP2012521768A (ja) * 2009-03-27 2012-09-20 ジモジェネティクス・インコーポレイテッド 抗体−受容体の組み合わせを含む多特異的結合性タンパク質を用いるための組成物および方法
US20100305002A1 (en) * 2009-04-27 2010-12-02 Roswell Park Cancer Institute Reagents and Methods for Producing Bioactive Secreted Peptides
US9492495B2 (en) * 2010-05-14 2016-11-15 Max-Delbrueck-Centrum Fuer Molekulare Medizin Therapeutic use of agonists or antagonists of bradykinin receptor 1 or 2, for modulation collateral blood vessel growth
WO2012088563A1 (en) 2010-11-24 2012-07-05 Vegenics Pty Limited Vegfr-2-specific forms of vegf-d and vegf-c and uses thereof

Also Published As

Publication number Publication date
EP3013851A2 (en) 2016-05-04
US9920096B2 (en) 2018-03-20
US20160176929A1 (en) 2016-06-23
EP3013851A4 (en) 2016-12-28
WO2014207534A2 (en) 2014-12-31
JP2016528192A (ja) 2016-09-15
BR112015032554A8 (pt) 2018-01-23
WO2014207534A3 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
CY1122344T1 (el) Blautia stercosis και wexlerae για χρηση στην θεραπευτικη αγωγη φλεγμονωδων και αυτοανοσων νοσων
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
SV2017005419A (es) Triazolopirazinonas como inhibidores de pde1
ECSP14008556A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
BR112014030414A2 (pt) combinação de um imunoconjugado, composição farmacêutica, uso de um imunoconjugado, métodos de tratamento e de estímulo, kit e invenção.
EA201491550A1 (ru) Применение связывающего белка нейротрофинового рецептора p75ntr в терапевтических целях
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
ECSP13012462A (es) Inmunoglobulinas con dominio variable dual
MA34058B1 (fr) Formes de rifaximine, et leurs utilisations
MY167920A (en) HUMAN ANTIBODIES TO GFRα3 AND METHODS OF USE THEREOF
DOP2017000254A (es) Imidazopirazinonas como inhibidores de pde1
DOP2016000027A (es) Moduladores benzoimidazol-2-ilpirimidinas del receptor h4 de histamina
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
BR112015023074A2 (pt) agentes de ligação-met e uso dos mesmos
BR112015017241A2 (pt) doadores de nitroxil com índice terapêutico melhorado
BR112016023860A2 (pt) heterociclil sulfonas substituídas por heteroaril
MX2014013678A (es) Agentes para neutralizacion de influenza.
BR112013025001A2 (pt) derivados de pirazolo pirimidina
BR112014016937A2 (pt) terapia de combinação para o tratamento de desordens de audição e do equilíbrio
BR112017003334A2 (pt) variantes de desintegrina e usos farmacêuticos destas
ECSP16061208A (es) Quinazolin-thf-aminas como inhibidores de pde1
MX2016003293A (es) Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados.
DOP2016000263A (es) Quinazolin-thf-aminas halogenadas como inhibidores de pde1
BR112014032290A2 (pt) composições e métodos para tratar ou prevenir infecção de pneumovírus e doenças associadas.
EA201691335A1 (ru) Гексагидрофуропирролы в качестве ингибиторов pde1

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]